Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2012

View Archived Issues

Clinical results presented for the RTS,S/AS01 malaria vaccine

Novel pegylated camptothecin derivatives disclosed by Chinese researchers

Stanford University creates novel peptide therapeutics for leishmaniasis and trypanosomiasis

Pfizer reports topline results from phase III pregabalin trial in epilepsy

JCR's phase II/III stem cell trial completes enrollment

Xenetic reports phase I/IIa MS vaccine trial initiation in Russia

Incyte and Lilly present promising phase II data for baricitinib in rheumatoid arthritis

Novel 3D neuroblastoma-based in vitro culture model designed to investigate tauopathies

Researchers publish results of first-in-human trial of APR-246

Novel mGlu5 receptor modulators disclosed by Roche

New vaccines for birch pollen allergy presented by Teknologian Tutkimuskeskus

Santaris Pharma prepares novel antisense oligonucleotides

Bayer patents new TTK inhibitors

NeuroSearch designs new modulators of neurotransmission

CHMP recommends Exjade approval for non-transfusion-dependent thalassemia syndromes

Zytiga receives positive CHMP recommendation for castration-resistant prostate cancer

Brd1 gene knockout produces schizophrenia and depression phenotypes

Pluristem begins phase I/II trial of PLX cells in muscle injury

Amgen describes novel peptide agonist of the CaS receptor

Alexza Pharmaceuticals receives updated list of outstanding issues for Adasuve

Sobi files MAA to expand Kineret label

GlaxoSmithKline receives new FDA approval for Promacta

CFFT and Pfizer expand drug discovery collaboration

UCB begins phase III lacosamide study in Asia

FDA grants fast track status to OBI-1 for acquired hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...